Keywords: sclor, starts, pkc, study, cdt-fenofibrate, drugmaker, scolr
SCLOR starts PKC study of CDT-fenofibrate
Article | 16 April 2007
US drugmaker SCOLR Pharma has commenced pilot bioavailability testing in Canada of its immediate-release CDT-fenofibrate tablets in the treatment of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
